Novartis boosts involvement in anti-Covid treatment
The biotech company and the pharmaceutical giant want to develop and market a drug with a unique approach for the prevention and treatment of Covid-19.
Keystone/Alexandra Wey
Swiss pharmaceutical company Novartis says it has signed a deal with biotech firm Molecular Partners to develop, manufacture and commercialise an anti-Covid-19 treatment drug.
The Basel-based company said the option and licence agreement was aimed at boosting a programme consisting of two antiviral therapeutic candidates, MP0420 and MP0423.
“It is clear that this pandemic calls for not just scientific solutions, but also for collaboration between companies to provide treatments in an area of high unmet need,” Novartis said in a statement publishedExternal link on Wednesday.
Molecular Partners will be responsible for the conduct of phase 1 and 2 trials.
Under the terms of the agreement, Molecular Partners will receive an initial payment of CHF60 million ($66.1 million). If Novartis takes up the option to both drugs, it will pay another CHF150 million to the biotech company.
In August, the Swiss government signed an agreement with Molecular Partners for priority access to a drug being developed to treat those severely ill with Covid-19.
It gives Switzerland access to the first 200,000 doses of the medicine, as well as up to three million further doses when requested.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Trump tariffs: ‘I’m a bit perplexed’, says former US ambassador to Switzerland
This content was published on
The former US ambassador to Switzerland, Edward McMullen, says he is optimistic for the Alpine country with regard to the 31% tariff on imports imposed by US President Donald Trump.
Swiss Federal Court upholds Beny Steinmetz’s bribery conviction
This content was published on
Switzerland's highest court has upheld the conviction of French-Israeli mining magnate Beny Steinmetz for bribery of foreign public officials.
This content was published on
The Trump administration has imposed a 31% tariff on imports from Switzerland. Swiss President Karin Keller-Sutter has warned against "giving in to alarmism" in an interview published on Saturday,
This content was published on
Scientists have shown that bonobos combine their calls into complex sound sequences that resemble combinations of human words.
This content was published on
US parliamentarians have threatened the UN Human Rights Council with sanctions similar to those against the International Criminal Court (ICC).
This content was published on
Thanks to abundant snowfall, lift operators benefited from increased visitor numbers, with the number of guests jumping by 12% year-on-year.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche bids to co-develop potential oral Covid-19 treatment
This content was published on
The Basel-based company has partnered with Atea Pharmaceuticals to develop, manufacture and distribute the latter’s oral anti-Covid-19 treatment.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.